Subject(s)
Antineoplastic Agents , Cardiovascular Diseases , Neoplasms , Humans , Cardiovascular Diseases/prevention & control , Aged , Neoplasms/complications , Age Factors , Antineoplastic Agents/adverse effects , Heart Disease Risk Factors , Risk Assessment , Treatment Outcome , Aged, 80 and over , Risk FactorsABSTRACT
Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this affects cardiovascular and tumor biomarkers; exploring the role of cardiovascular biomarkers in the risk stratification and in the identification of chemotherapy-induced cardiotoxicity; and providing a summary of the novel potential biomarkers in this clinical setting.
